About Arch Pharmalabs Limited
Data last updated:
Arch Pharmalabs Limited is a public limited company based in Mumbai, Maharashtra, India. The company is currently undergoing Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code, 2016. Management control has been transferred to an insolvency professional. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 02 April 1993.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24231MH1993PLC150891. Its GSTIN is 27AACCM0306Q1ZE (Maharashtra). The company holds 10 GST registrations, of which 5 are active.
The company has an authorised share capital of ₹3,000 Cr and a paid-up capital of ₹156.48 Cr. It was formerly known as Sibra Pharmaceuticals Limited and Avant Papers Private Limited. It is led by directors including Ajit Annu Kamath (Managing Director) and Rajendra Padmanabhan Kaimal (Whole-Time Director).
Its last annual general meeting (AGM) was held on 29 December 2023, and its latest financial statements are for the year ended 31 March 2023. The registered office is at Unit No. 301 302 And 303 H Wing 3rd Floor Tex Centre, Off Saki Vihar Road Chandivali Andheri East Mumbai, Maharashtra, India – 400072.
As per the financials filed for FY 2023, the company reported a revenue of ₹1,344.16 Cr, a growth of 2% compared to the previous year. For the same year it recorded a net profit of ₹122.12 Cr (net margin 9.1%) and EBITDA of ₹182.85 Cr (EBITDA margin 13.6%). Revenue has grown at a compounded annual rate (CAGR) of 27% over three years and 40% over five years.
The company has about 412 employees on its provident fund (EPFO) records. Its group structure includes 3 subsidiaries.
The company is associated with 1 brand: Arch Pharmalabs. As per MCA filings, the company has open charges of ₹5,668.24 Cr and satisfied charges of ₹311.84 Cr on record. Court records list 337 cases involving the company, including 25 filed by the company and 312 filed against it; 56 cases are pending. The company has 10 deals on record (7 funding rounds, 1 rights issue, 1 secondary share transfer), with disclosed funding of ₹680.88 Cr; the latest was in March 2023. Its 7 peer companies in the Pharma industry (API Manufacturers, Contract Research), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 3 smaller; the largest is Teva Api India Private Limited with revenue of ₹1,456.07 Cr. The company has 56 MSME Form 1 returns on record between 2012 and 2023, listing 2,332 overdue payments to 163 micro and small suppliers.
The last known website on record is archpharmalabs.com.
Company details
Name history
Arch Pharmalabs has undergone 3 name changes throughout its history. The company was previously known as Sibra Pharmaceuticals Limited, Avant Papers Private Limited, and Arch Commerz Limited. The current legal name is Arch Pharmalabs Limited.
| Company Name | Status |
|---|---|
| Arch Pharmalabs Limited | Current |
| Sibra Pharmaceuticals Limited | Previous |
| Avant Papers Private Limited | Previous |
| Arch Commerz Limited | Previous |
CIN history
Arch Pharmalabs has one previous CIN (Corporate Identification Number): U24231MH2005PTC150891. The current CIN is U24231MH1993PLC150891, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24231MH1993PLC150891 | Current |
| U24231MH2005PTC150891 | Previous |
Contact details
Arch Pharmalabs Limited's registered office is in Mumbai, Maharashtra. Its website is archpharmalabs.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressUnit No. 301 302 And 303 H Wing 3rd Floor Tex Centre, Off Saki Vihar Road Chandivali Andheri East Mumbai, Maharashtra, India – 400072
- IndustryPharma, API Manufacturers, Pharma Contract R&D
To see the full contact details of Arch Pharmalabs Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Arch Pharmalabs operates one associated brand: Arch Pharmalabs. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| API manufacturer & supplier, also offering custom synthesis and contract manufacturing services | archpharmalabs.com |
Business activity
The main business activity of Arch Pharmalabs is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Arch Pharmalabs Limited, buy the company report.
Financials of Arch Pharmalabs Limited
FY 2023 filings availableArch Pharmalabs Limited reported revenue of ₹1,344.16 Cr (up 2% YoY) for FY 2023.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 40% over five years, including 2% growth in the latest year. EBITDA rose 1% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | ₹1,344.16 Cr | ||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹182.85 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹122.12 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 13.6% | ||||
| Net Profit Margin | 9.1% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Arch Pharmalabs Limited, buy the company report.
Board of directors and KMP of Arch Pharmalabs Limited
Arch Pharmalabs Limited currently reports 5 directors and 1 key managerial person. 26 former directors have served the organization.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Vikas Bijay Kedia | Company Secretary | 18 Nov 2017 | 8 Years 11 Months | As last reported |
| Sunil Mansukhlal Pitroda | Director | 02 May 2017 | 9 Years 5 Months | As last reported |
| Anshul Gupta Also directs: Finkonnect Capital Advisors LLP, Afro Connect Consultancy Services Private Limited, Yajur Veda Impex Private Limited and 1 more | Irp/Rp/Liquidator | 30 Apr 2025 | 1 Years 5 Months | As last reported |
| Ajit Annu Kamath Also directs: Vitalife Pharma Limited, Tack Commosales LLP, Arch Agro Industries Private Limited and 5 more | Managing Director | 01 Nov 2003 | 22 Years 11 Months | As last reported |
| Rajendra Padmanabhan Kaimal Also directs: Vitalife Pharma Limited, Arch Agro Industries Private Limited, Amra Renal Care Limited and 5 more | Whole-Time Director | 01 Nov 2003 | 22 Years 11 Months | As last reported |
| Ashish Mohan Ujagare Also directs: Vitalife Pharma Limited | Whole-Time Director | 14 Jun 2018 | 8 Years 4 Months | As last reported |
Peer comparison
Arch Pharmalabs Limited is compared with the 7 companies closest to it by revenue in the Pharma industry (API Manufacturers, Contract Research), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Teva Api India Private Limited | ₹1,456.07 Cr (FY 2025) | 7.0% | Mumbai, Maharashtra, India | |||
| Dhanuka Laboratories Limited | ₹1,424.06 Cr (FY 2025) | -3.0% | Chennai, Tamil Nadu, India | |||
| Harman Finochem Limited | ₹1,376.43 Cr (FY 2025) | 27.0% | Mumbai, Maharashtra, India | |||
| Cohance Lifesciences Limited | ₹1,362.25 Cr (FY 2024) | 0.0% | Mumbai, Maharashtra, India | |||
| Arch Pharmalabs Limitedthis company | ₹1,344.16 Cr (FY 2023) | ₹122.12 Cr | 9.1% | 2.0% | 412 | Mumbai, Maharashtra, India |
| Shilpa Medicare Limited | ₹1,309.57 Cr (FY 2025) | 13.0% | Raichur, Karnataka, India | |||
| Solara Active Pharma Sciences Limited | ₹1,292.08 Cr (FY 2025) | 0.0% | Thane, Maharashtra, India | |||
| Vasudha Pharma Chem Limited | ₹1,174.19 Cr (FY 2025) | 1.0% | Hyderabad, Telangana, India |
To see the full peer comparison of Arch Pharmalabs Limited, buy the company report.
Auditor
Arch Pharmalabs Limited is audited by Neha C Shah & Associates for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Neha C Shah & Associates | FY 2023 | 147435W |
Shareholding
The shareholding of Arch Pharmalabs Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Arch Pharmalabs Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 29 Mar 2022 | 100571158 | Others | ₹32 Cr | Open | |
| 20 Jul 2021 | 100463954 | Others | ₹5 Lakh | Open | |
| 27 May 2021 | 100464383 | Others | ₹200 Cr | Open | |
| 04 Dec 2017 | 100190938 | Others | ₹200 Cr | Open | |
| 27 Sep 2013 | 10450741 | Others | ₹582.3 Cr | Open |
To see the full charge records of Arch Pharmalabs Limited, buy the company report.
Total charge records: 65 View all charges
Deals & funding
Arch Pharmalabs Limited has 10 deals on record (7 funding rounds, 1 rights issue, 1 secondary share transfer), with disclosed funding of ₹680.88 Cr; the latest was in March 2023.
Deals on record (5 of 10)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2023 | Funding round | ₹149.49 Cr | Investors: Nipro Pharmapackaging India Private Limited |
| Dec 2017 | Funding round | ₹111.92 Cr | Investors: Arch Impex Private Limited , JM Financial Asset Reconstruction Company Limited , Arch Pharmachem Ltd |
| Nov 2017 | Acquisition | Undisclosed | Buyer: Neuland Laboratories Ltd. Seller: Arch Pharmalabs Limited |
| Oct 2015 | Funding round | ₹12.16 Cr | Investors: Arch Agro Industries Private Limited |
| Oct 2012 | Funding round | ₹150 Cr | Investors: A M R Investments Private Limited |
To see the full deal history of Arch Pharmalabs Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Arch Pharmalabs Limited has 337 court cases on record: 25 filed by Arch Pharmalabs, 312 filed against it. 56 cases are pending and 281 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 229 | 223 | 35 |
| High courts | 85 | 66 | 12 |
| NCLAT | 14 | 14 | 9 |
| NCLT | 9 | 9 | 0 |
Cases on record (5 of 337)
| Court | Type of case | Party | Status |
|---|---|---|---|
| NCLAT, NCLAT New Delhi | Interim or miscellaneous application | Filed against the company by M/S Krishna Solvechem Limited | Pending |
| NCLAT, NCLAT New Delhi | Court case (Caveat) | Filed against the company by M/S Krishna Solvechem Limited | Pending |
| NCLAT, NCLAT New Delhi | Insolvency matter | Filed against the company by M/S Krishna Solvechem Limited | Pending |
| NCLAT, NCLAT New Delhi | Interim or miscellaneous application | Filed against the company by Omkara Assets Reconstruction Privatelimited | Pending |
| NCLAT, NCLAT New Delhi | Interim or miscellaneous application | Filed against the company by JM Financial Asset Reconstruction Company Limited | Pending |
To see the full case history of Arch Pharmalabs Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Arch Pharmalabs Limited was last rated by Icra on 27 Aug 2018.
| Rating agency | Rated on | Rating |
|---|---|---|
| Icra | 27 Aug 2018 |
To see the full credit ratings and regulatory alerts of Arch Pharmalabs Limited, buy the company report.
MSME payment delays
Arch Pharmalabs Limited has 56 MSME Form 1 returns on record between 2012 and 2023, listing 2,332 overdue payments to 163 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 163)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Simson Pharma Limited | |||
| an individual supplier | |||
| an individual supplier | |||
| an individual supplier | |||
| an individual supplier |
To see the full MSME payment records of Arch Pharmalabs Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Arch Pharmalabs has 3 subsidiary companies and 1 associated company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares held |
|---|---|---|
| Arch Finechemicals Limited | U24110TG1993PLC015533 | |
| Arch Life Sciences Limited | U24239TG2003PLC042232 | |
| Vitalife Pharma Limited | U24299MH2021PLC356633 |
To see the full group structure of Arch Pharmalabs Limited, buy the company report.
Employees & EPFO
Arch Pharmalabs Limited has a workforce of 412 employees on its EPFO records as of Apr 08, 2024, across 4 active EPFO establishments.
GST
Arch Pharmalabs has 10 GST registrations: 5 active and 5 cancelled or inactive. The first 4 active GSTINs are listed below.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AACCM0306Q1ZE | Maharashtra | Active | 01 Jul 2017 |
| 27AACCM0306Q2ZD | Maharashtra | Active | 01 Apr 2020 |
| 27AACCM0306Q3ZC | Maharashtra | Active | 17 Apr 2025 |
| 06AACCM0306Q1ZI | Haryana | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Arch Pharmalabs Limited, buy the company report.
Recent activity
Arch Pharmalabs Limited has 32 board changes on record since 2003: 6 appointments and 26 cessations. The latest: Anshul Gupta was appointed as Irp/Rp/Liquidator on 30 Apr 2025.
151 earlier events are in the company report.
News
Frequently asked questions
Arch Pharmalabs is undergoing "Corporate Insolvency Resolution Process" (CIRP) under the Insolvency and Bankruptcy Code, 2016. Management control has been transferred to an insolvency resolution professional. The company may not be able to independently enter into new commitments during this period. This is a high-risk status - verify the resolution status before any engagement.
Arch Pharmalabs is a company under insolvency, formerly operating as a public limited company based in Mumbai, Maharashtra, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 02 April 1993 and is registered under CIN U24231MH1993PLC150891. Caution is advised - the company may not have the legal capacity to fulfil new agreements.
Arch Pharmalabs has 6 current directors and KMP:
- Ajit Annu Kamath - Managing Director
- Rajendra Padmanabhan Kaimal - Whole-Time Director
- Ashish Mohan Ujagare - Whole-Time Director
- Sunil Mansukhlal Pitroda - Director
- Vikas Bijay Kedia - Company Secretary
- Anshul Gupta - Irp/Rp/Liquidator
The latest financial statements of Arch Pharmalabs on record with the MCA are for the year ended 31 March 2023. Its last annual general meeting was held on 29 December 2023. Year-wise statements from 2015 are in the company report.
The CIN (Corporate Identification Number) of Arch Pharmalabs is U24231MH1993PLC150891. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Arch Pharmalabs has open charges of ₹5,668.24 Cr and satisfied charges of ₹311.84 Cr as per latest MCA filings.
Arch Pharmalabs has 337 court cases on record: 25 filed by the company and 312 filed against it. 56 are pending. Most are in the district courts.
Arch Pharmalabs was incorporated on 02 April 1993. It is registered with the Registrar of Companies, Mumbai.
Arch Pharmalabs has 10 deals on record (7 funding rounds, 1 rights issue, 1 secondary share transfer), with disclosed funding of ₹680.88 Cr; the latest was in March 2023.
The peers of Arch Pharmalabs by revenue are Teva Api India Private Limited, Dhanuka Laboratories Limited, Harman Finochem Limited, Cohance Lifesciences Limited, Shilpa Medicare Limited and 2 more, all in the Pharma industry (API Manufacturers, Contract Research), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Anshul Gupta was appointed as Irp/Rp/Liquidator on 30 Apr 2025. Sanjay Garg ceased to be Irp/Rp/Liquidator on 30 Apr 2025. Ashish Mohan Ujagare ceased to be Additional Director on 29 Dec 2018. Arch Pharmalabs has 32 board changes on record in total.
Arch Pharmalabs has 56 MSME Form 1 returns on record between 2012 and 2023, listing 2,332 overdue payments to 163 micro and small suppliers. The latest return was filed on 29 Aug 2023.